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Original Article
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Background: The relationship between survivin and extranodal, nasal-type natural killer/T cell lymphoma 
(ENKTCL) was unclearly established yet. We here studied the potential prognostic roles of survivin and its 
implication as a target in ENKTCL therapy. 
Methods: ENKTCL patients’ peripheral blood were collected and tested by ELISA. ENKTCL cell lines 
were cultured with or without survivin inhibitor and tested by MTT and Flow cytometry. According to the 
gene expression profiles from the ArrayExpress Archive under E-TABM-702, survivin co-regulated cluster 
was established by Coupled Two-way Clustering Algorithm. 
Results: Seventeen point six percent of total 17 ENKTCL patients were serum survivin-positive. These 
patients had poorer outcome than that of negative cases (P<0.01). Analysis of survivin co-regulation genes 
in ENKTCL revealed that survivin was significantly involved in pluripotency, drug resistance, cell cycle 
and proliferation, indicating that it should be one of key regulators in ENKTCL and might be a latent 
therapeutic target. Our results just showed that YM155, a survivin inhibitor, had strong anti-tumor effect 
on ENKTCL cell lines in a dose dependent manner. It increased sub-G1 phase population and reduced G1- 
and G2-M phase populations (P<0.05). In addition, combining YM155 with DDP induced a larger decrease 
in cell viability than either agent alone and had a higher inhibition rate than Bliss index, suggesting their 
synergistic inhibition. 
Conclusions: We concluded that survivin was a potential prognostic marker and a critical regulatory 
molecule in the pathological process of ENKTCL. It would be a promising target in drugs discovery for 
ENKTCL therapy. 
Keywords: Extranodal, nasal-type natural killer/T cell lymphoma (ENKTCL); survivin; prognosis; therapeutic 
target
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Introduction 
Extranodal, nasal-type natural killer/T cell lymphoma 
(ENKTCL) is a special subtype of non-Hodgkin’s 
lymphoma with a geographical and ethnical predilection 
for Asian and South American populations. A conservative 
estimate in China is that 11.0% of malignant lymphomas 
newly diagnosed each year are ENKTCL, the second 
large proportion among all types of lymphoma (1). Up to 
60–80% of patients were classified as Ann Arbor Stage I/II 
at the time of initial diagnosis. However, the traditional and 
classical chemotherapy CHOP was administrated in these 
stage I/II patients, the 5-year overall survival (OS) was less 
than 50%. For those patients of stage III/IV or relapsed 
and/or refractory disease, 1-year OS was just only 55% (2). 
Some new therapy regimens, composing of L-asparaginase, 
cisplatin, carboplatin, oxaliplatin, ifosfamide, methotrexate, 
etoposide, gemcitabine, and/or dexamethasone, showed a 
promising overall response rate (81–100%) and a 2–3-year 
OS (78–87.5%) in stage I/II patients (3-7). But 5-year OS 
was only about 60% and much less than that of other types 
of early lymphomas (8,9). Development of new effective 
drugs is thus desired to improve the survival of ENKTCL 
patients. 
Survivin belongs to the family of inhibitors of apoptosis 
proteins (IAPs). In normal situation, survivin is prominently 
expressed during embryonic development and absently 
or little expressed in normal differentiated adult tissues. 
But survivin expression is abnormally upregulated in cells 
transformed into malignancy. Over-expression of survivin 
was closely associated with cancer cells proliferation, 
apoptosis, autophagy, anti-cancer-drugs resistance, and 
cancer angiogenesis (10-16). In addition, high level of 
survivin was detected in peripheral blood of patients with 
some kinds of cancers and might be a good marker for 
prognosis (17-20).
Due to the important roles of survivin in malignancies, 
drug development targeting survivin may yield cumulative 
benefits. YM155, as one of the low molecular weight 
antagonists, inhibits the gene transcription through binding 
with the Sp1 of survivin promoter. Some researches claimed 
that YM155 alone or combined with other anti-cancer 
drugs can inhibit proliferation, increase apoptosis, reverse 
drug resistance, and improve radiation sensitivity of cancer 
cells (21-24). A few phases I/II clinical trials were operated 
in advanced cancer patients to test the safety and tolerance 
of YM155 (25-28).
There were a couple of reports about the association 
between ENKTCL and survivin. The positive survivin 
expression in ENKTCL tissue samples from Singapore 
was 97% (22/23) (29). The positive rate of serum survivin 
in ENKTCL from Korea was 27.3% and significantly 
correlated with the level of EBV-DNA, tumor loading and 
OS (30). However, the roles of survivin in ENKTCL were 
not clearly understood yet. We here aimed to further study 
survivin as a therapy target for ENKTCL.
Methods
Patients and samples
All 17 patients received the unified treatment which was 
L-asparaginase-basic chemotherapy and local radiotherapy. 
After obtaining informed consent, we collected peripheral 
venous blood from ENKTCL patients at the time of 
initial diagnosis for testing serum survivin, from 09/2008 
to 03/2014. For comparison, serum samples from healthy 
adults were collected in 03/2014 as well. The diagnosis of 
NKTCL was made according to the 2008 World Health 
Organization classification of tumors of the hematopoietic 
and lymphoid tissues. This study was approved by the 
West China Hospital of Sichuan University (ID of ethics 
approval: SCHX-2014-0302).
Cell line and reagents 
The human NKTCL cell line SNK-10 was obtained 
from Fudan University (Shanghai) and cultured in 
RPMI1640 (Thermo Scientific) supplemented with 15% 
heat-inactivated human serum, 700 IU/mL of IL-2, 
100  U/mL of  penic i l l in  sod ium,  100  mg/mL of 
streptomycin sulfate, and 0.5 μg/mL amphotericin B at 
37 ℃ in a humidified air atmosphere containing 5% CO2. 
The cell line was authenticated by testing membrane 
markers using flow cytometry (31). YM155 monobromide 
(YM155) was purchased from Selleck Chemicals Company 
and dissolved in dimethyl sulfoxide (DMSO), DDP from 
Qilu Pharmaceutical Co., Ltd.
ELISA 
The blood was placed in room temperature for 4 hours for 
being fully solidified, and was centrifuged by 3,500 rpm/min. 
The serum samples were then sub-packaged and stored 
at −80 ℃ until tested for levels of survivin. An ELISA Kit 
(Human Survivin ELISA kit, Abcam) was used to determine 
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the concentration of survivin in the serum samples. The 
instruction was carefully followed.
Establishment of BIRC5 co-regulated Cluster
Gene expression profiles of 51 samples were obtained from 
the ArrayExpress Archive under E-TABM-702, including 
7 ENKTCL biopsies, 2 ENKTCL cell lines, 16 PTCL 
NOS biopsies, 6 normal NK-cells, and 20 normal B-cell 
samples (32). We removed those genes with both coefficient 
of variation and quartile coefficient of dispersion across 
all samples less than 0.15. Total 11,254 genes were left for 
following analysis.
MTT assay 
In vitro cell proliferation was measured using MTT assay. 
Cells in the logarithmic phase of growth were seeded into 
96-well culture plates at 1×104 cells per well. After treatment 
with different concentrations of YM155, or vehicle control, 
or different concentration combinations of YM155 with 
DDP, 100 μL of MTT solution (1 mg/mL) were added 
to each well, and the cells were further incubated at 37 ℃ 
for 4 hours. The supernatant was replaced with dimethyl 
sulfoxide (DMSO) to dissolve formazan production. The 
absorbance at wave length 570 nm was measured and 
630 nm adjusted using micro-ELISA reader. The inhibition 
rates were calculated from 3 independent assays.
Flow cytometry 
After YM155 treatment, cells were collected and fixed in 
chilled 70% ethanol, resuspended in PBS, and treated with 
RNaseA. Propidium iodide (PI) was added to cells, and 
samples were analyzed with flow cytometry in FACSCalibur 
(BD Biosciences). Cell-cycle profile analysis of DNA 
histograms of integrated red fluorescence was performed 
with ModFit LT software (VeritySoftware, Inc, Topsham). 
Mean values were obtained from three independent assays.
Analysis for synergy
The Bliss Additivism model was used to classify the 
effect of combining two agents as additive, synergistic, 
or antagonistic. A theoretical curve was calculated for 
combined inhibition using the equation: Bliss index Ebliss = EA 
+ EB - EA×EB, where EA and EB are the fractional inhibitions 
obtained by drug A alone and drug B alone at specific 
concentrations. The combined effect of the two drugs was 
judged as follows: Synergistic if EA+B > Ebliss; Additive if EA+B 
= Ebliss; and antagonistic if EA+B < Ebliss.
Statistical analysis 
Kaplan Meier plot was used to demonstrate survival time. 
Pearson coefficient was used to analyze the correlation. The 
coupled two-way clustering algorithm was used to obtain 
a stable cluster (33). The molecular signatures database 
was used for the gene set enrichment analysis (34), and 
the principle component analysis was used to visually and 
globally characterize the difference among various types of 
samples. Probit analysis (Logit model) was used to evaluate 
the half maximal inhibitory concentration (IC50) of agents. 
Inhibition rates were calculated as the means of at least 
three different experiments ± standard deviation (SD). The 
results were analyzed by one-way ANOVA, and P<0.05 was 
considered to be statistically significant.
Ethics approval
This study was conducted in State Key Laboratory 
of Biotherapy (SKLB), Sichuan University which was 
established by the Ministry of Sciences and Technology 
in China. SKLB is a highly-regarded, comprehensive 
and multidisciplinary research center in China. Through 
the seamless integration of basic research, preclinical 
development, translational and clinical medicine, an efficient 
and fully integrated technology chain for the discovery 
and development of innovative drug candidates has been 
established in a single institute. It has been exempted from 
ethics as a primary research project.
Results 
Serum survivin level in ENKTCL patients
Peripheral venous blood of 17 patients, who were 
diagnosed as ENKTCLs with their primary sites in the 
upper aerodigestive tract according to the WHO criteria, 
were collected. The correlations between patients’ clinical 
characteristics and the level of serum survivin were shown 
in Table 1. Their averaged age was 44.9 years (ranged from 
15 to 74 years). Three of them (17.6%) were positive of 
serum survivin. Their concentrations were 56.22, 13.89, and 
21.03 pg/mL, respectively. The survivin level was negatively 
correlated with OS (R=−0.644, P=0.005), and positively 
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correlated with the level of serum lactic dehydrogenase 
(LDH) (R=0.627, P=0.007). The serum survivin was 
negative in all 16 donators. 
Survival analysis 
Up to the following-up deadline (12/2015), the median 
survival time of patients was 2.8 years with range from 
0.4 to 7.2 years. For all patients, 2-year OS was 58.8%, 
and 3-year OS was 44.1% (Figure 1A). Among eight dead 
patients (47.1%), three of them had positive serum survivin. 
Their survival times were typically short, being 0.4, 0.6 
and 1.5 years, respectively. In negative survivin group, 
2- and 3-year OS was 71.4%, and 53.6% respectively, 
clearly higher than those of overall patients. The survival 
difference between survivin positive and negative patients 
was statistically significant (P<0.001), that was, survival time 
of patients with negative was significantly longer than that 
of positive patients (Figure 1B).
The role of survivin co-regulated gene set
By using the coupled two-way clustering algorithm, we 
observed that BIRC5 (survivin gene) belonged to a large 
stable cluster (G72) with 4,419 genes, which could hardly 
differentiate between ENKTCL (S5) and normal NK-cell 
samples (S4) (Figure S1). To identify a systematic cluster 
of genes which are putatively co-regulated with survivin in 
ENKTCL, we considered only those ENKTCL biopsies 
and normal NK-cell samples. A stable 139-gene cluster 
(Table S1) was putatively survivin co-regulated because of 
their highly correlation of expressions (Figure 2A). By the 
principle component analysis, we noticed that ENKTCL 
was close to the activated NK-cells compared to the resting 
NK-cells (Figure 2B). Gene set enrichment analysis over this 
cluster also indicated that ENKTCLs were more activated, 
less differentiated, and earlier-effector-like than NK-cells 
(Table 2). According to the gene ontology analysis, this 
cluster was enriched with cell cycle and proliferation genes, 
consistent with the survivin functions. Additionally, it was 
significantly related to pluripotency and drug resistances. 
All of them suggested that survivin was involved in the 
process of ENKTCL (Table 2). 
Anti-tumor effect of YM155 alone and combined with 
Cisplatinum (DDP)
As shown in Figure 3A,B, YM155 alone had a strong 
anti-tumor effect in a dose dependent manner. Basically, 
the higher dose was applied, the higher inhibition rate 
was observed. When the dose went up to 50 nm/L or 
above, there was a big jump of inhibition rate following 
time extending, almost reaching 100% inhibition at 
48 h. Statistically, both of time and dose were correlated to 
inhibition rate (P<0.001). Figure 3C,D showed that YM155 
treatment increased sub-G1 phase population, and reduced 
G1- and G2-M phase populations significantly (P<0.05). 
We then investigated the anti-tumor effect of YM155 
combined with DDP. The IC50 was 17.47±4.82 nm/L for 
YM155 and 1.54±0.1 μg/mL for DDP. The dosages of 
YM155 combined with DDP were determined according to 
the IC50. The percentage of cell growth inhibition induced 
Table 1 Patients’ characteristics and their correlation with serum survivin
Characteristics Percentage (%) R& (correlated with serum survivin)
Stage I, 23.5%; II, 58.8%; III, 5.9%; IV, 11.8% 0.302
Sex Female, 41.2%; male, 58.8% 0.074
Age Mean, 44.9 years (range, 15 to 74 years) −0.394
IPI scores 0, 29.4%; 1, 35.3%; 2, 29.4%; 3, 5.9% 0.413
LDH Increased, 35.3%; normal, 64.7% 0.627** (P=0.007)
B symptom Absent, 47.1%; present, 52.9% 0.127
ECOG scores 0, 41.2%; 1, 470.1%; 2, 11.8% 0.346
OS Mean, 3 years (range, 0.4 to 7.2 years) −0.644** (P=0.005)
Survivin Positive, 17.6%; negative, 82.4% 1.0
**, correlation is significant at the 0.01 level (2-tailed); &, correlation coefficient. IPI, international prognosis index; LDH, Lactic 
dehydrogenase; ECOG, Eastern Cooperative Group performance score; OS, overall survival time.
Annals of Translational Medicine, Vol 7, No 14 July 2019 Page 5 of 11
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by combination of YM155 with DDP was much higher 
than either agent alone, even higher than the Bliss index 
(Figure 4), declaring that YM155 and DDP were synergistic. 
Discussion 
Survivin plays an important role in many kinds of malignant 
tumors. For example, atypical survivin level was reported 
in peripheral blood of pancreatic cancer patients and might 
act as a diagnostic and prognostic marker (19). The patients 
were shown to have obviously higher survivin than that of 
normal adults, with a median concentration of 99.4 pg/mL 
in patients and 41.36 pg/mL in normal adults (P<0.001). 
Higher level of serum survivin was significantly associated 
with perineural invasion, venous invasion, lymph node 
status (N stage), cell differentiation, and recurrence. Median 
OS of normal serum survivin group was much longer than 
that of elevated group (26 vs. 9 months), and 5-year OS 
was 38.4% for the normal serum survivin group and 9.3% 
for the high serum survivin group, indicating that survivin 
was an independent prognostic factor for pancreatic cancer. 
Similar results were also reported in gallbladder cancer, 
breast cancer and ovarian cancer, with the median value of 
survivin being 4.1–112.4 pg/mL (17,18,20).
For ENKTCLs, Kim et al. reported that survivin was 
detected in peripheral blood and the positive rate was 
27.3% in 66 patients (ranged from 0.8 to 165.0 pg/mL). 
In addition, serum survivin-positive patients showed a 
significant association with elevation of EBV DNA and 
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Figure 1 Survival curve of ENKTCL patients. (A) Survival curve for all patients; (B) survival comparison between patients with survivin 










































































































Figure 2 Survivin co-regulated gene set. (A) Expression Heatmap of BIRC5-coregulated Cluster based on the coupled two-way clustering 
algorithm; (B) samples’ relationship by the principle component analysis (ReNK: Resting NK-cell; AcNK: Activated NK-cell).
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Table 2 Gene sets enriched with genes in the BIRC5 co-regulated cluster
Corresponding 
functions
Gene set name P value Description
Cell cycle CELL_CYCLE_GO_0007049 <1E-6 Genes annotated by the GO term GO:0007049
CELL_CYCLE_PROCESS <1E-6 Genes annotated by the GO term GO:0022402
CELL_CYCLE_PHASE <1E-6 Genes annotated by the GO term GO:0022403
KEGG_CELL_CYCLE <1E-6 Cell cycle
BENPORATH_CYCLING_GENES <1E-6 Genes showing cell-cycle stage-specific expression
Proliferation CELL_PROLIFERATION_GO_0008283 <1E-6 Genes annotated by the GO term GO:0008283
BENPORATH_PROLIFERATION <1E-6 Set ‘Proliferation Cluster’: genes defined in human 
breast tumor expression data
Pluripotency MUELLER_PLURINET <1E-6 Genes constituting the PluriNet protein-protein 
network shared by the pluripotent cells
WONG_EMBRYONIC_STEM_CELL_CORE <1E-6 Core ESC-like gene module
BHATTACHARYA_EMBRYONIC_STEM_CELL <1E-6 The stemness signature: genes up-regulated and 
common to 6 human embryonic stem cell lines tested
BENPORATH_ES_1 <1E-6 Genes overexpressed in human embryonic stem cells 
according to 5 or more out of 20 profiling studies
GSE27786_LSK_VS_NKCELL_UP 0.000025 Genes up-regulated in comparison of LSK versus NK 
cells
GSE27786_LIN_NEG_VS_CD8_TCELL_UP 0.000025 Genes up-regulated in comparison of lineage negative 
versus CD8 T cells
Treatment WANG_RESPONSE_TO_GSK3_INHIBITOR_
SB216763_DN
<1E-6 Genes down-regulated in RS4;11 cells in response to 
SB216763
CAFFAREL_RESPONSE_TO_THC_DN <1E-6 Genes down-regulated in EVSA-T cells treated THC




<1E-6 Genes down-regulated in at least 8 of 11 sarcoma cell 
lines by trabectedin




<1E-6 Genes down-regulated in response to nutlin-3a
BLUM_RESPONSE_TO_SALIRASIB_DN <1E-6 Genes down-regulated in response to salirasib in a 
panel of cancer cell lines with constantly active HRAS
SMIRNOV_RESPONSE_TO_IR_6HR_DN <1E-6 Genes down-regulated in B lymphocytes at 6 h after 
exposure to 10 Gy dose of ionizing radiation
Activation GSE7764_IL15_TREATED_VS_CTRL_NK_
CELL_24H_UP
<1E-6 Genes up-regulated in comparison of NK cells treated 
with IL15 versus untreated NK cells
GSE22886_UNSTIM_VS_IL2_STIM_NKCELL_
DN
<1E-6 Genes down-regulated in comparison of unstimulated 
NK cells versus those stimulated with IL2 at 16 h
GSE22886_UNSTIM_VS_IL15_STIM_
NKCELL_DN
<1E-6 Genes down-regulated in comparison of unstimulated 
NK cells versus those stimulated with IL15 at 16 h
Table 2 (continued)
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(P<0.05) (30). In our study, the positive rate of survivin was 
17.6% in ENKTCL patients’ serum (ranged from 13.9 
to 56.22 pg/mL). And the level of serum survivin was also 
negatively correlated to OS. Patients with negative survivin 
had longer survival time than those with positive survivin. 
Otherwise, we found that serum survivin has significant 
association with serum LDH. Because high serum LDH 
is well known to be a worse factor for non-Hodgkin 
lymphoma’ prognosis, we inferred that survivin should be a 
factor for poor outcome of ENKTCL patients. 
Above all, different concentration of serum survivin were 
reported by different researches over virous cancers (median 
value ranged from 4.1 to 176 pg/mL) and the positive 
detection rate was low, suggesting that survivin still needs to 
be further studied as a prognostic marker in clinic. A unified 
protocol and samples from multiple resources were desired 
for further researches. 
At mRNA level, cell-free BIRC5 (survivin-encoded 
gene) was found to be significantly increased in serum of 
colorectal cancer (CRC), and closely correlated with tumor 
differentiation, regional lymph node metastasis and TNM 
stage. High serum BIRC5 mRNA expression corresponded 
to a poorer OS (35). These prompted that serum BIRC5 
mRNA may be an interesting target for ENKTCL as well.
To further characterize the roles of survivin in 
ENKTCL, transcriptomic profiles were collected from 
the ArrayExpress Archive under E-TABM-702 (32). We 
obtained a stable 139-gene cluster which was supposed 
to be BIRC5 co-regulated. This cluster was enriched 
with genes related to pluripotency and drug resistances, 
in addition to the expected cell cycle and proliferation, 
strongly supporting that BIRC5 should be one of the targets 
critical for ENKTCL transformation and development. We 




Gene set name P value Description
Undifferentiation LEE_EARLY_T_LYMPHOCYTE_UP <1E-6 Genes up-regulated at early stages of progenitor T 
lymphocyte maturation compared to the late stages
RHODES_UNDIFFERENTIATED_CANCER <1E-6 Genes commonly up-regulated in undifferentiated 
cancer relative to well-differentiated cancer




<1E-6 Genes up-regulated in poorly differentiated thyroid 
carcinoma compared to normal thyroid tissue
Effector-like GSE3982_NKCELL_VS_TH1_DN <1E-6 Genes down-regulated in comparison of NK cells 
versus Th1 cells
GSE3982_NKCELL_VS_TH2_DN <1E-6 Genes down-regulated in comparison of NK cells 
versus Th2 cells
GSE9650_NAIVE_VS_EFF_CD8_TCELL_DN <1E-6 Genes down-regulated in comparison of naive CD8 T 
cells versus effector CD8 T cells
GSE9650_EFFECTOR_VS_MEMORY_CD8_
TCELL_UP
<1E-6 Genes up-regulated in comparison of effector CD8 T 
cells versus memory CD8 T cells
KAECH_NAIVE_VS_DAY8_EFF_CD8_TCELL_
DN
<1E-6 Genes down-regulated in comparison of naive versus 
effector CD8 T cells (day 8)
KAECH_DAY8_EFF_VS_DAY15_EFF_CD8_
TCELL_UP
<1E-6 Genes up-regulated in comparison of effector CD8 T 
cells (day 8) versus those (day 15)
KAECH_DAY8_EFF_VS_MEMORY_CD8_
TCELL_UP
<1E-6 Genes up-regulated in comparison of effector CD8 T 
cells (day 8) versus memory CD8 T cells (day 40+)
Survival SHEDDEN_LUNG_CANCER_POOR_
SURVIVAL_A6
<1E-6 Up-regulation of these genes in patients with non-
small cell lung cancer predicts poor survival outcome
Zhang et al. The significance of survivin in ENKTCL
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activated, less differentiated, and earlier-effector-like stage 
compared to normal NK-cells. Therefore, BIRC5 might 
be involved in maintaining this pluripotency, activation, 
and undifferentiation within ENKTCL cells. BIRC5 
inhibitor might be one of the potential drugs for ENKTCL 
treatment.
YM155, one of survivin inhibitors, inhibits survivin gene 
expression by suppressing promoter activity. It showed 
multiple functions such as anti-tumor proliferation and 
inducing apoptosis in cancer cell lines. It could also increase 
the sensitivity of radiotherapy and reverse drug-resistance. 
For example, YM155 in combination with bendamustine/
rituximab showed a greater therapeutic efficacy than 
either agent alone, induced a greater sub-G1 phase 
population, and made a survival time extension in DLBCL 
xenografts (22). YM155 sensitized ovarian cancer to DDP, 
osteosarcoma to doxorubicin and CRC to 5-Fu (24,36,37). 
The safety and feasibility of YM155 were reported in phase 
I/II clinical trials in patients with refractory/recurrence 
lymphoma and solid malignances (25-28). But not 
ENKTCL yet. In this study, our results showed that YM155 
resulted a greater sub-G1 population, depressed ENKTCL 
cells proliferation and induced apoptosis and necrosis. Our 
results demonstrated that the combination effect of YM155 
and DDP was synergistic, suggesting that YM155 combined 
with DDP was potential regimen for advanced/refractory 
Figure 3 Anti-tumor effect of YM155 alone. (A) The curve of inhibition rate followed by the varieties of YM155 concentrations (0, 3.125, 
6.25, 12.5, 25, 50, 100 and 200 nm/L); (B) the curve of inhibition rate followed by time changes (6, 12, 24, 48 and 72 h); (C) after YM155 
treatment for 24 h, cell-cycle distribution was detected via flow cytometry; (D) the difference of population in different cell-cycle stages 
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ENKTCL treatments. 
Conclusions 
This research has shown that survivin was a prognostic 
marker for the ENKTCL patients and a key regulatory 
molecule in the pathological process of ENKTCL. Survivin 
was also proved to be a promising target in the drug 
discovery for ENKTCL. In addition, the combined effect 
of YM155 and DDP was synergistic. Our results provide 
a starting point for future study about YM155 as a potent 
drug for ENKTCL therapy. However, this research just 
included a small sample. So, the results need to be further 
study. And now we are still collecting the blood samples 
and tissues samples and planning to establish animal model, 
doing more researches in ENKTCL.
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Figure 4 The effect after YM155 combined with DDP treatment for 24 h. Each bar represents the mean ± SD of inhibition rate from three 
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Table S1 Categories in which 139 genes in the BIRC5 co-regulated cluster might be involved
Genes name Cell Cycle Proliferation Pluripotency Activation Undifferentiation Effector-like Effector-like Anti-drug favorite Survival
THOC4 +
MAD2L1 + + + + + + + + +
ASPM + + + +
PBK + + + + + +
ANLN + + + + + +
CCNA2 + + + + + + + +
FAM72A
BUB1 + + + + + + + +
CDKN3 + + + + + + + +
CEP55 + + + +
GAPDH +
E2F8 + + + + + + +
MND1 + + +
DLGAP5 + + + + + + +
KIF14 + + + +
TPX2 + + + + + + +
HMMR + + + + + +
FANCI + + + + + +
CCNB1 + + + + +
PSRC1 + + +
CENPA + + + + + + +
WHSC1 + + + + +
KIF11 + + + + + + +
TTK + + + + + + + +
CKAP5 + + + +
KIF23 + + + + + + +
CDCA2 + + +
NUF2 + + + +
SPC25 + + +
CDK1 + + + + + + + +
KIF15 + + + + +
NEK2 + + + + + + + + +
ECT2 + + + +
NCAPG + + + + + + +
SKA1 + + + +
RRM2 + + + + + + + +
DEPDC1B + +
GANAB
KIF20A + + + + + +
MLF1IP + + + + + +
TPM4 + +
TMEM48 + + + + +
PRC1 + + + + + + + +
KIAA0101 + + + + + + +
CENPE + + + + +
CDC25C + + + + + + + +
PLK1 + + + +
CHEK1 + + + + + + +
CKS1B + + + + + + + +
SNRNP40 + +
BUB1B + + + + + +
KIF4A + + + + +
RRM1 + + + + + +
CASC5 + +
HJURP + + +
CENPH + +
AURKB + + + + + + +
EBP +
MKI67 + + + + + + +
FBXO5 + + + +
CCNB2 + + + + + + + +
UBE2C + + + + + + +
YWHAH + + + +
KIF2C + + + + + + + +
KIF18B + + + + +
CDCA3 + + + + + + +
FOXM1 + + + +
BIRC5 + + + + + + + + +
CDCA8 + + + + + +
NCAPG2 + + + + + +
GTSE1 + + + + + +
PARVB +
NCAPH + + + + + + +
TRIP13 + + + + + +
CKAP2L + +
NT5DC2 +
HN1 + + + + +
CDC20 + + + + + + + +
ELMO1 +
MASTL + + + +
MELK + + + +
CDCA5 + + + + +
RAD54B + + +
ERCC6L + + + +
DHFR + + + +
ARHGAP11A + + +
TK1 + + +
KPNA2 + + + + + + + + +




GPSM2 + + + + + +
ESPL1 + + + + +
CDC45 + + + + + + +
SKA3 +
DDX11 + + +
KIF22 + + + + +
WDR90 +
GCAT + +
TACC3 + + + + + +
RBBP8 + + + + + +










SRPK1 + + +
POC1A +
AGBL5 +
RAD54L + + + + + + + +
CENPM + + + +
DNA2 + + + + +
CIT + + +
CARHSP1 + + + +





UBE2T + + + + +
APOBEC3B + +
AURKA + + + + + + + + +
CENPF + + + + + +
CKS2 + + + + + + + + +
C6orf108 + +
PTTG1 + + + + + + + +
SPAG5 + + + + +
EZH2 + + + + + + +
MRPL37 + +
C15orf23 + + +
HMGB3 + + + + + +
EIF4A3 + +
TRIP10 +
